Patient-Controlled Analgesia Pumps Market: Global Industry Analysis and Forecast (2023-2029)

 

Patient-Controlled Analgesia Pumps Market size was valued at USD 420.10 Million in 2022 and the total Patient-Controlled Analgesia Pumps revenue is expected to grow at a CAGR of 5.4% from 2023 to 2029, reaching nearly USD 605.58 Million.

Patient-controlled analgesia (PCA) is used to treat acute, chronic, postoperative, and labor pain. PCA is a method of delivering intravenous pain medication at a prescribed continuous rate via a specialized PCA infusion pump. Additionally, the patient may self-administer prescribed bolus infusions intermittently or small doses of opioids, such as fentanyl, morphine, hydromorphone, or meperidine to manage breakthrough pain. The clinical application of this technology has been growing year by year. Insufficient pain relief can have certain consequences, which may delay the recovery and hospitalization time, increase the number of readmissions, reduce patient satisfaction, and increase overall healthcare costs. As a result, the demand for analgesia pumps is increased significantly, thereby driving the patient-controlled analgesia pumps market growth.

In addition, the increasing elderly population and growing inclination for surgical operations, combined with technological advancements that allow procedures to be performed in the workplace as well as at home for pain management, are expected to be the primary drivers driving the patient-controlled analgesia pumps market growth. Patient-controlled pumps provide enhanced patient pain management and care, providing various advantages over traditional modules. Additionally, the COVID-19 pandemic has initiated a home healthcare setting trend, to reduce hospital visits, which is expected to increase the demand for patient-controlled analgesia (PCA) pumps. Various patient-controlled analgesia pumps are effective for pain management in a homecare setting. These pumps are small and light, which makes them the perfect choice for ambulatory and bedside usage. As a result, the rising demand for PCA pumps in home care settings is expected to benefit the patient-controlled analgesia pumps market during the forecast period.To know about the Research Methodology :- Request Free Sample Report

Competitive Landscapes:

The Patient-controlled analgesia pumps industry is moderately competitive with several significant market players all across the world. Key industry participants are pursuing a number of both organic and inorganic growth strategy in to expand their product and service portfolios and strengthen their market position in the global market. In addition, Companies are focusing on Research and Development (R&D) activities, and the adoption of technologically advanced solutions to gain a competitive edge. For instance,

1. In August 2022, Baxter's innovative Novum IQ syringe infusion pump (SYR) with Dose IQ Safety Software received 510(k) approval from the US Food and Drug Administration. Baxter is a global leader in infusion treatment and pain management, and the Novum IQ pump is an important contribution to the company's portfolio of products.

2. In March 2022, Shanghai MicroPort Lifesciences Co. Ltd received marketing certification from China's NMPA for their self-developed AutoEx Chemotherapy Infusion Pump (AutoEx). It is the first authorized product in the company's intelligent oncology pain solutions portfolio.

3. In January 2022, ICU Medical, a California-based company acquired the Smiths Medical Division. When united with ICU Medical's existing operations, the combined firms establish a prominent infusion treatment corporation with roughly USD 2.5 billion in pro forma combined revenues.

Hence, such developments in the industry are expected to increase the patient-controlled analgesia pumps market size during the forecast period.

The Future of Patient-Controlled Analgesia in Clinical Spaces

As patient-controlled analgesia becomes increasingly prevalent, a thorough set of double-blind and randomized controlled trials must be conducted to further elucidate the safety and effectiveness of this relatively novel method. Errors in this delivery method can be addressed through the adoption of superior programming and improved training for assemblers, anesthesiologists, nurses, and patients, along with fail-safes to ensure the safety of the user.  As a result, Patient-controlled analgesia pumps have promising potential for revolutionizing the future of pain management in medical spaces, which is expected to benefit the patient-controlled analgesia pumps market players during the forecast period.

Although further research is necessary, some studies have highlighted the advantages of patient-controlled analgesia. According to research, testing the effectiveness of sublingual sufentanil tablet system (PCA) vs nurse-controlled morphine (control) for inducing analgesic in postoperative cardiac surgery patients found adequate pain relief and reduced opioid usage in the PCA group, which is validated by other research. In addition, patient-controlled analgesia offers better pain relief after cardiac surgery. Besides that, PCA increases patient satisfaction with the post-operative process.
Patient-Controlled Analgesia Pumps Market Dynamics:
Increasing prevalence of Fibromyalgia and other chronic diseases

Fibromyalgia, often known as widespread pain, is a chronic (long-term) illness characterized by widespread pain and sensitivity, as well as exhaustion and difficulty sleeping. The rising incidence of fibromyalgia is expected to drive the growth of the patient-controlled analgesia pumps market during the forecast period. According to the analysis, around 4 million American residents, or 2% of all adults, suffer from fibromyalgia. Although there is no known cause of fibromyalgia, it is curable and controllable with a variety of pain management approaches, including the usage of a patient-controlled analgesia pump. As a result, the high prevalence of chronic pain disorders such as fibromyalgia enhances the use of patient-controlled analgesia pumps and drives market growth throughout the forecast period.

In addition, the rising number of people with chronic pain disorders such as arthritis, cancer, and fibromyalgia, along with technical improvements that include better safety features in PCA pumps, is further expected to drive the growth of the patient-controlled analgesia pumps market. In 2022, for example, around 20% of individuals in the United States suffering from chronic pain. Additionally, the prevalence of chronic pain is expected to increase in the future years as diabetes and cancer survival rates rise. This chronic pain condition necessitates the use of analgesia pumps to provide timely pain relief, resulting in a rapid increase in product demand, thereby driving the patient-controlled analgesia pumps market growth.

Besides that, the incorporation of cutting-edge technology in PCA pumps benefits better pain recuperation and increases patient satisfaction, boosting the growth of the patient-controlled analgesia pumps market. For example, Acromed Chroma infusion pumps incorporate cutting-edge pain management technology, allowing patients to self-administer bolus analgesic medication. This allows patients to regulate their discomfort and feel comfortable while reducing the need for on-site help from medical personnel.

Emerging economies are a potential market

Emerging economies such as India, China, Indonesia, Thailand, Turkey, Vietnam, Singapore, etc. are expected to offer lucrative growth opportunities for the patient-controlled analgesia pumps market players. Rapidly increasing geriatric populations in developing and under-developing countries are expected to be the major growth driver for the patient-controlled analgesia pumps market during the forecast period. Aging increases vulnerability to illnesses, Because of weakened immunity and degeneration. The senior population has grown dramatically, making people more vulnerable to ailments such as cardiovascular disease, stroke, diabetes, stomach diseases, cancer, intestinal illnesses, and others all across the world.

In addition, the increasing burden of chronic diseases, high adoption of technologically advanced products, developing healthcare industry, and favorable government initiatives for the expansion of healthcare infrastructure are some of the factors expected to increase the product demand, thereby driving the patient-controlled analgesia pumps market growth during the forecast period. Thanks to increased demand for improved healthcare services, large government investments in improving healthcare infrastructure, and the expansion of the medical tourism industry, the healthcare industry in emerging economies is growing rapidly. In addition, an increase in the occurrence of pain cases due to an increase in surgical procedures that require pain management therapies increases the demand for affordable patient-controlled analgesia (PCA) pumps and is expected to drive patient-controlled analgesia pumps market growth throughout the forecast period.
Patient-Controlled Analgesia Pumps Market Segment Analysis:
By Type, the global patient-controlled analgesia pumps market is segmented into electronic analgesia pumps and mechanical analgesia pumps. The electronic analgesia pumps segment dominated the market with the highest market share of 72% in 2022. The segment is further expected to grow at a CAGR of 5.6% and maintain its dominance by 2029. The wireless analgesia system is a PCA information management system based on the Internet combined with an electronic analgesia pump and wireless data transmission. The electronically controlled analgesia pump is injected into the liquid by the motor, and the injection of the liquid is more stable.

It consists of an electronic infusion control system and a liquid storage infusion system. The liquid storage bag is a one-time use. It uses a high-performance single-chip microcomputer and control circuit to effectively control the infusion flow rate. The basic flow rate, PCA amount, and locking time can be set according to the patient’s specific conditions. In addition, Electronic analgesic pumps are effective and safe for Patient-controlled Epidural Analgesia (PCEA) during labor and postoperative pain treatment, thereby increasing segment demand.

The mechanical analgesia pump segment is expected to grow at a significant CAGR during the forecast period. Thanks to the advantages offered by mechanical analgesia pumps such as small size, easy portability, low price, and no programming errors, etc. led to a strong preference for mechanical analgesia pumps among healthcare professionals and patients. However, according to analysis, mechanical analgesia pumps may affect the analgesic pump due to loss of elasticity, or the inability of the drug solution to enter due to blockage of the connected infusion catheter. As a result, the demand for mechanical analgesia pumps is expected to hamper and restrain segment growth.

By Applications, the Oncology segment held the largest market share of 38.4% in 2022. The segment is expected to grow at a CAGR of 5.2% and is expected to dominate the global patient-controlled analgesia pumps market by 2029. The high prevalence of cancers all around the world is expected to benefit the segment's growth. Cancer pain is frequently characterized as a throbbing, pressing, burning, or tingling sensation that can be treated with PCA pumps. Hence, demand for PCA pumps is expected to increase rapidly in conjunction with the increasing cancer burden.

For Instance, according to the Canadian Cancer Statistics 2021, approximately 229,200 new cancer cases were found in Canada in 2021. Similarly, according to research issued in 2022 by the CMAJ Group, around 233,900 Canadians were diagnosed with cancer in 2022. As a result of the increased number of new cancer cases, the demand for pain treatment is expected to increase considerably, which may be accomplished using patient-controlled analgesia pumps. Physicians provide very strong opioid medicines such as hydro morphine, morphine, and fentanyl via patient-controlled analgesia (PCA) infusion to relieve intolerable pain. The increasing use of PCA pumps in such conditions to improve quality of life is expected to drive patient-controlled analgesia pumps market growth during the forecast period.

Similarly, a rise in patient satisfaction with cancer pain treatment through the use of patient-controlled analgesia pumps contributes significantly to market growth. According to analysis, the programmable patient-controlled analgesia (PCA) pump, for example, allows patients to manage pain on high demand, responds quickly to the patient's changing demands, and eliminates analgesic delay. For chronic severe cancer pain, the PCA dramatically lowered effective titration and average pain score. As a result, the demand for PCA pumps for cancer pain treatment is expected to drive segment growth.
Patient-Controlled Analgesia Pumps Market Regional Insights:
The North American region held the largest market share of 36.5% and dominated the global Patient-

Controlled Analgesia Pumps market in 2022. The region is further expected to grow at a CAGR of 5.8% and maintain its dominance by 2029. The increasing prevalence of chronic diseases such as diabetes, heart disease, chronic lung disease, Alzheimer’s, etc., the rising number of cancer patients, the high burden of road accidents and injuries, and other ailments related to pain relief are some of the factors expected to drive the regional market growth. In addition, increasing governmental fundings related to healthcare industry development, growing research and development activities, and substantial growth in healthcare infrastructure are further factors expected to support the North American patient-controlled analgesia pumps market growth during the forecast period.

In the United States, 1.9 million new cancer cases were diagnosed, and 609,360 cancer deaths were estimated in 2022. Cancer is the second most common cause of death in the US, exceeded only by heart disease. One person dies every 34 seconds in the United States from cardiovascular disease. In addition, more than 130 million adults are living with diabetes or prediabetes in the United States in 2022. As a result, the increasing prevalence of chronic diseases in the region is expected to increase the demand for patient-controlled analgesia significantly. Additionally, with an increasing generic population base, as well as the growing awareness of the benefits of patient-controlled analgesia pumps, is expected to benefit from the patient-controlled analgesia pumps market growth in the region.

The Asia-Pacific region is expected to grow at the highest CAGR of 6.2% during the forecast period. The rising prevalence of chronic illnesses, along with increased knowledge of new and advanced technologies, is expected to drive market growth, particularly in emerging countries such as Vietnam, Thailand, India, and China. In addition, the growing aging population, increasing road fatalities, increased awareness about pain treatment, and improved healthcare facilities and infrastructure in the region are further expected to support the Asia-Pacific patient-controlled analgesia pumps market growth during the forecast period.
Patient-Controlled Analgesia Pumps Market Scope: Inquiry Before Buying



Patient-Controlled Analgesia Pumps Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
US $ 420.10 Bn.


Forecast Period 2023 to 2029 CAGR:
5.5%
Market Size in 2029:
US $ 605.58 Bn.


 Segments Covered:
by Type
1. Electronic
2.Mechanical


by Application
1. Diabetes
2. Oncology
3. Gastroenterology
4. Hematology
5.Others


by End-use
1. Hospitals
2. Specialty Clinics
3. Ambulatory Surgical Centers
4. Home Care Settings



Patient-Controlled Analgesia Pumps Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Patient-Controlled Analgesia Pumps Market Key Players:
1. Baxter International Inc.
2. B. Braun Melsungen AG
3. BD (Becton Dickinson, and Company)
4. Smith’s Group plc
5. Fresenius SE & Co. KGaA
6. ICU Medical
7. Micrel Medical Devices
8. Avante Health Solutions
9. Ace Medical
10. Terumo Corporation
11. Johnson and Johnson
12. Abbott
13. Pfizer Inc. (Hospira)
14. SCW Medicath
15. KGaA
16. Henan Tuoren Medical Device Co., Ltd.
17. Changzhou Medical Bioengineering Co., Ltd.
18. Arcomed AG
19. Medica Surgical
20. Medtronic
21. Nevro Corporation
22. Primetech Corporation
23. F. Hoffmann-La Roche Ltd
24. Greatbatch Medical
25. Neuropace

FAQs:

1. What are the growth drivers for the Patient-Controlled Analgesia Pumps market?
Ans. The increasing prevalence of chronic pain diseases such as arthritis, cancer, and fibromyalgia, is expected to be the major driver for the Patient-Controlled Analgesia Pumps market.

2. What is the major restraint for the Patient-Controlled Analgesia Pumps market growth?
Ans. Stringent government regulations are expected to be the major restraining factor for the Patient-Controlled Analgesia Pumps market growth.

3. Which region is expected to lead the global Patient-Controlled Analgesia Pumps market during the forecast period?
Ans. North America is expected to lead the global Patient-Controlled Analgesia Pumps market during the forecast period.

4. What is the projected market size & growth rate of the Patient-Controlled Analgesia Pumps Market?
Ans. The Patient-Controlled Analgesia Pumps Market size was valued at USD 420.10 Million in 2022 and the total Patient-Controlled Analgesia Pumps revenue is expected to grow at a CAGR of 5.4% from 2023 to 2029, reaching nearly USD 605.58 Million.

5. What segments are covered in the Patient-Controlled Analgesia Pumps Market report?
Ans. The segments covered in the Patient-Controlled Analgesia Pumps market report are Type, Applications, End-use, and Region.